Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVONASDAQ:LPCNNASDAQ:PYXSNASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$8.47+0.6%$9.40$1.80▼$22.57$73.71M-0.231.33 million shs68,303 shsLPCNLipocine$3.58-3.0%$3.27$2.68▼$11.79$19.15M1.5235,137 shs27,039 shsPYXSPyxis Oncology$1.23+2.5%$1.06$0.83▼$5.39$76.20M1.15739,771 shs471,961 shsTELOTelomir Pharmaceuticals$2.10-4.5%$2.85$1.98▼$8.40$62.50M0.17137,692 shs109,322 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed+0.59%-3.53%-6.10%+271.49%-55.44%LPCNLipocine-2.98%-10.28%+15.48%+5.92%-45.76%PYXSPyxis Oncology+2.50%+1.65%+13.89%-3.91%-68.46%TELOTelomir Pharmaceuticals-4.55%-16.00%-17.32%-46.29%-62.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRVOCervoMed3.3333 of 5 stars4.44.00.00.01.91.70.6LPCNLipocine1.9786 of 5 stars3.53.00.00.02.30.00.6PYXSPyxis Oncology1.5358 of 5 stars3.40.00.00.03.10.80.6TELOTelomir Pharmaceuticals1.4618 of 5 stars3.80.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVOCervoMed 2.89Moderate Buy$27.63226.15% UpsideLPCNLipocine 3.00Buy$10.00179.33% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00631.71% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00614.29% UpsideCurrent Analyst Ratings BreakdownLatest LPCN, CRVO, PYXS, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.003/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025PYXSPyxis OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/18/2025CRVOCervoMedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.003/18/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $21.003/17/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/13/2025CRVOCervoMedJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.003/13/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $14.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVOCervoMed$7.14M10.32N/AN/A$1.30 per share6.52LPCNLipocine$3.67M5.21N/AN/A$3.83 per share0.93PYXSPyxis Oncology$16.15M4.72N/AN/A$2.81 per share0.44TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)LPCNLipocine-$16.35M-$1.02N/A∞N/AN/A-19.17%-17.60%8/6/2025 (Estimated)PYXSPyxis Oncology-$73.79M-$1.59N/AN/AN/AN/A-36.22%-28.76%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%N/ALatest LPCN, CRVO, PYXS, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million3/18/2025Q4 2024PYXSPyxis Oncology-$0.33-$0.32+$0.01-$0.60N/A$16.15 million3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVOCervoMedN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVOCervoMedN/A15.0415.04LPCNLipocineN/A12.9712.97PYXSPyxis OncologyN/A7.337.33TELOTelomir PharmaceuticalsN/A1.941.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVOCervoMed25.15%LPCNLipocine9.11%PYXSPyxis Oncology39.09%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRVOCervoMed35.40%LPCNLipocine6.12%PYXSPyxis Oncology10.60%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVOCervoMed48.70 million3.93 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataPYXSPyxis Oncology6061.95 million53.64 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/ALPCN, CRVO, PYXS, and TELO HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual SeparationMay 21 at 10:56 PM | marketwatch.comTelomir Pharmaceuticals Appoints New Chief Financial OfficerMay 21 at 5:55 PM | tipranks.comTelomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease INDMay 21 at 9:00 AM | accessnewswire.comTelomir PharmaceuticalsMay 19, 2025 | thepharmaletter.comTelomir unveils new drug candidate against resistant bacteriaMay 16, 2025 | investing.comTelomir Pharma touts breakthrough in drug-resistant infectionsMay 16, 2025 | thepharmaletter.comTELO Announces Exciting DiscoveryMay 15, 2025 | msn.comTelomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market OpportunityMay 15, 2025 | accessnewswire.comTELO Announces Promising Aging Reversal Test ResultsMay 8, 2025 | msn.comTelomir Pharmaceuticals Unveils Promising Preclinical Data on Telomir-1May 7, 2025 | tipranks.comTelomir Pharmaceuticals (TELO) Projected to Post Earnings on MondayMay 7, 2025 | marketbeat.comTelomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic DysphoniaMay 7, 2025 | accessnewswire.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 6.57%May 3, 2025 | aaii.comGeode Capital Management LLC Has $1.71 Million Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)May 2, 2025 | marketbeat.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Down 7.25%April 29, 2025 | aaii.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 10.93%April 2, 2025 | aaii.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Down 17.60%March 31, 2025 | aaii.comTelomir Pharmaceuticals, Inc. (TELO)March 21, 2025 | finance.yahoo.comTELO Study Shows Cancer-Related BreakthroughMarch 19, 2025 | msn.comTelomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal modelMarch 19, 2025 | msn.comTelomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study ShowsMarch 19, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPCN, CRVO, PYXS, and TELO Company DescriptionsCervoMed NASDAQ:CRVO$8.47 +0.05 (+0.59%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.54 +0.06 (+0.77%) As of 05/23/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Lipocine NASDAQ:LPCN$3.58 -0.11 (-2.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.60 +0.02 (+0.42%) As of 05/23/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Pyxis Oncology NASDAQ:PYXS$1.23 +0.03 (+2.50%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.20 -0.02 (-2.03%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Telomir Pharmaceuticals NASDAQ:TELO$2.10 -0.10 (-4.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.13 +0.03 (+1.43%) As of 05/23/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
